Skip to main content

The Orpyx Sensory Insole Program

Backed by a Robust and Growing Body of Evidence

Committed to Research

The Only Plantar RPM Solution Backed by a Randomized Controlled Trial¹

In a randomized controlled trial of patients with diabetes and a history of foot ulcers, the Orpyx technology, delivering real-time pressure alerts, demonstrated a substantial reduction in ulcer recurrence.

Among patients who wore the insoles for at least 4.5 hours per day, ulcer incidence was reduced by 86% compared to standard care.¹

This highlights the critical role of consistent use and real-time data in supporting early intervention and long-term limb preservation.

Significant Reduction in Foot Ulcer Occurrence and Healthcare Costs with SOC + Orpyx Technology²

This cost-effectiveness study evaluated standard of care (SOC) alone versus SOC combined with the Orpyx technology. Cost analysis was conducted over both short-term (3 months) and long-term (18 months) periods to assess clinical and economic outcomes.

The peer-reviewed study demonstrated sustained prevention benefits over 18 months, with substantial healthcare cost savings and a significant reduction in event occurrences.2

Exploring the Value of Continuous Plantar Temperature Monitoring for Diabetic Foot Health Management: Observations from a Prospective Study

There is increasing evidence that plantar temperature monitoring can reduce the incidence and recurrence of DFUs. While daily monitoring has been shown to help detect early signs of inflammation, by continuously tracking intra-day temperature asymmetries with the Orpyx Sensory Insoles, this research reveals that plantar temperature signals often fluctuate significantly throughout the day. 

These findings suggest that single daily readings may be insufficient to reliably capture meaningful changes, potentially leading to missed warning signs or false alarms.

Clinical Research

1. Abbot CA, et al. Innovative intelligent insole system reduces diabetic foot ulcer recurrence at plantar sites: a prospective, randomised, proof-of-concept study. Lancet Digital Health Oct. 2019; 1: e308–18. (Study was conducted with first generation SurroSense Rx® which has the same pressure algorithm as the Orpyx technology) 2. Najafi B et al, Cost effectiveness of smart insoles in preventing ulcer recurrence for people in diabetic foot remission. Wound Care Management (2018) Volume 1(1): 5-7. 3. Data on file—Continuous_temperature_monitoring. *Study was conducted with first generation SurroSense Rx® which has the same pressure algorithm as Orpyx Sensory Insoles.